Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Lynn Henry

Showing results (141-150 of 195) with videos related to

Pageof 20
Sort By:
Pharmacogenomics|July 24, 2020
Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathyYongzhen Chen, Fang Fang, Kelley M Kidwell, et al.
BMC Cancer|October 15, 2025
Longitudinal multi-omics analyses of chemotherapy-induced peripheral neuropathy in response to taxanesAnukriti Sharma, Ken B Johnson, Alper Sen, et al.
Breast Cancer Research and Treatment|February 13, 2019
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletionLandry K Kamdem, Jingyue Xi, Brandi L Clark, et al.
Pharmacogenomics|June 14, 2019
Effects of <i>SLCO1B1</i> polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozoleJacqueline M Dempsey, Kelley M Kidwell, Christina L Gersch, et al.
Pharmacogenomics|January 23, 2016
Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclinesDaniel L Hertz, Megan V Caram, Kelley M Kidwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2019
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORxFabrice Andre, Nofisat Ismaila, N Lynn Henry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2019
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario GuidelineN Lynn Henry, Mark R Somerfield, Vandana G Abramson, et al.
Research Square|September 11, 2023
Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221Ciao-Sin Chen, Gary Zirpoli, G Thomas Budd, et al.
Cancer Chemotherapy and Pharmacology|May 30, 2024
Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221Ciao-Sin Chen, Gary Zirpoli, G Thomas Budd, et al.
Cancer Medicine|November 16, 2024
Capturing Chemotherapy and Radiotherapy Dose Among Breast Cancer Patients With the Utah All-Payer Claims Database Compared With Gold-Standard AbstractionAlzina Koric, Chun-Pin Esther Chang, Shane Lloyd, et al.
Pageof 20

Showing results (141-150 of 195) with videos related to

Sort By:
Pageof 20
Pharmacogenomics|July 24, 2020
Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathyYongzhen Chen, Fang Fang, Kelley M Kidwell, et al.
BMC Cancer|October 15, 2025
Longitudinal multi-omics analyses of chemotherapy-induced peripheral neuropathy in response to taxanesAnukriti Sharma, Ken B Johnson, Alper Sen, et al.
Breast Cancer Research and Treatment|February 13, 2019
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletionLandry K Kamdem, Jingyue Xi, Brandi L Clark, et al.
Pharmacogenomics|June 14, 2019
Effects of <i>SLCO1B1</i> polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozoleJacqueline M Dempsey, Kelley M Kidwell, Christina L Gersch, et al.
Pharmacogenomics|January 23, 2016
Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclinesDaniel L Hertz, Megan V Caram, Kelley M Kidwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2019
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORxFabrice Andre, Nofisat Ismaila, N Lynn Henry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2019
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario GuidelineN Lynn Henry, Mark R Somerfield, Vandana G Abramson, et al.
Research Square|September 11, 2023
Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221Ciao-Sin Chen, Gary Zirpoli, G Thomas Budd, et al.
Cancer Chemotherapy and Pharmacology|May 30, 2024
Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221Ciao-Sin Chen, Gary Zirpoli, G Thomas Budd, et al.
Cancer Medicine|November 16, 2024
Capturing Chemotherapy and Radiotherapy Dose Among Breast Cancer Patients With the Utah All-Payer Claims Database Compared With Gold-Standard AbstractionAlzina Koric, Chun-Pin Esther Chang, Shane Lloyd, et al.
Pageof 20